Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

Core Insights - Pelthos Therapeutics Inc. has reported its financial results for legacy operations, marking the last report before the merger with Channel Therapeutics and the private placement financing [1] - The company completed a merger with Channel Therapeutics and closed a $50.1 million private placement to support the launch of ZELSUVMI™ [2] Financial Overview - The private placement financing was led by strategic investors, with shares of Series A Preferred Stock locked up until December 31, 2025 [3] - Pelthos has an estimated market capitalization of approximately $55 million, which could rise to about $165 million upon conversion of all Series A Preferred Stock [3] Product Launch - ZELSUVMI (berdazimer) topical gel was launched on July 10, 2025, as the first FDA-approved at-home treatment for molluscum contagiosum [4] - The product is a nitric oxide-releasing gel effective for treating molluscum infections, which affect an estimated 16.7 million people in the U.S. [4][9] Operational Developments - The company has built out its management and operational infrastructure, hiring 50 territory sales managers to support the commercial launch of ZELSUVMI [5][7] - The team now consists of over 90 employees, enhancing the company's capacity for market penetration [5] Management Commentary - The CEO emphasized the focus on execution and the successful launch of ZELSUVMI, positioning the company for future growth [8] - The company plans to invest in awareness programs for ZELSUVMI and is in discussions to acquire another FDA-approved pediatric infectious disease product [8] Market Context - Molluscum contagiosum is a highly contagious viral skin condition, with significant prevalence among children, leading to a substantial market opportunity for ZELSUVMI [9][10]